Free List Of Top 10 Neurodegenerative Disorder Gene Therapy Companies

The field of gene therapy for neurodegenerative disorders has seen significant advancements in recent years, with several companies pioneering innovative approaches to address these debilitating conditions. In the United States, numerous companies have emerged as leaders in this space, harnessing cutting-edge technology and groundbreaking research to develop potential treatments. These companies are at the forefront of efforts to combat neurodegenerative disorders, offering hope to millions of individuals and their families who are affected by these devastating conditions.

Overview of the Top 10 Neurodegenerative Disorder Gene Therapy Companies in the US

1. Sector: Biotechnology

– Company: Voyager Therapeutics

– Year Founded: 2013

– Annual Revenue: $45 million

– Description: Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Their innovative approach involves the delivery of gene therapy to the brain to address neurodegenerative disorders. Their lead candidate, VY-AADC for Parkinson’s disease, has shown promising results in clinical trials.

– Website: [Voyager Therapeutics](https://voyagertherapeutics.com/)

2. Sector: Biopharmaceutical

– Company: Axovant Gene Therapies

– Year Founded: 2014

– Annual Revenue: $36 million

– Description: Axovant Gene Therapies is dedicated to developing and commercializing innovative gene therapies for neurological conditions, including Parkinson’s disease and GM1 gangliosidosis. The company is actively advancing a pipeline of potential treatments, leveraging gene therapy to address the underlying causes of these disorders.

– Website: [Axovant Gene Therapies](https://axovant.com/)

3. Sector: Biotechnology

– Company: uniQure N.V.

– Year Founded: 1998

– Annual Revenue: $60 million

– Description: uniQure N.V. is a leading gene therapy company that focuses on developing treatments for patients with severe genetic disorders and neurodegenerative diseases. Their innovative platform enables the delivery of gene therapies to address a wide range of conditions, offering new hope for patients and their families.

– Website: [uniQure N.V.](https://www.uniqure.com/)

4. Sector: Biotechnology

– Company: Sangamo Therapeutics

– Year Founded: 1995

– Annual Revenue: $84 million

– Description: Sangamo Therapeutics is a clinical-stage biotechnology company that pioneers genomic medicines to transform the lives of patients with serious genetic diseases. They are dedicated to advancing innovative gene therapies for neurodegenerative disorders such as Huntington’s disease and Alzheimer’s disease.

– Website: [Sangamo Therapeutics](https://www.sangamo.com/)

5. Sector: Biotechnology

– Company: REGENXBIO Inc.

– Year Founded: 2008

– Annual Revenue: $58 million

– Description: REGENXBIO Inc. is a leading clinical-stage biotechnology company that focuses on developing life-changing gene therapies for a wide range of genetic and neurodegenerative disorders. Their platform enables the delivery of gene therapy to potentially address the underlying causes of these conditions.

– Website: [REGENXBIO Inc.](https://www.regenxbio.com/)

6. Sector: Biotechnology

– Company: Prevail Therapeutics

– Year Founded: 2017

– Annual Revenue: $30 million

– Description: Prevail Therapeutics is a biotechnology company focused on developing gene therapies for patients with neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Their innovative approach aims to slow or halt the progression of these debilitating conditions.

– Website: [Prevail Therapeutics](https://www.prevailtherapeutics.com/)

7. Sector: Biotechnology

– Company: Voyager Therapeutics

– Year Founded: 2014

– Annual Revenue: $42 million

– Description: Atalanta Therapeutics is a biotechnology company that is pioneering the development of R interference (Ri) therapies for neurodegenerative diseases, including frontotemporal dementia and amyotrophic lateral sclerosis (ALS). Their innovative approach aims to silence the genes responsible for these conditions.

– Website: [Atalanta Therapeutics](https://atalantatx.com/)

8. Sector: Biotechnology

– Company: Spark Therapeutics

– Year Founded: 2013

– Annual Revenue: $110 million

– Description: Spark Therapeutics is a leading gene therapy company that focuses on developing transformative treatments for patients with genetic and neurodegenerative diseases. Their innovative approach aims to address the underlying genetic causes of these conditions, offering potential long-term benefits to patients.

– Website: [Spark Therapeutics](https://sparktx.com/)

9. Sector: Biotechnology

– Company: Denali Therapeutics

– Year Founded: 2015

– Annual Revenue: $75 million

– Description: Denali Therapeutics is a biotechnology company that is dedicated to developing effective therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Their innovative approach involves targeting key pathways associated with these conditions to potentially slow or halt disease progression.

– Website: [Denali Therapeutics](https://www.denalitherapeutics.com/)

10. Sector: Biotechnology

– Company: Cerevel Therapeutics

– Year Founded: 2018

– Annual Revenue: $25 million

– Description: Cerevel Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, including neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. Their research efforts aim to address the underlying mechanisms of these conditions.

– Website: [Cerevel Therapeutics](https://www.cerevel.com/)

These companies represent the vanguard of gene therapy for neurodegenerative disorders in the United States, leading the way in pioneering treatments that may offer hope to millions of individuals affected by these debilitating conditions. Through their commitment to innovative research and development, they are shaping the future of healthcare by striving to combat and ultimately conquer neurodegenerative diseases.